non-small cell lung cancer

08/02/2016

JCP Editors

J Russel Hoverman, MD, PhD, Texas Oncology, next spoke about the performance of clinical pathways in practice. Texas Oncology has used clinical pathways for the last 10 years. In collaboration with Aetna and with US...

J...

08/02/2016

Journal of Clinical Pathways

Research in Review

Two Studies Support Immunotherapeutic Agent As First-Line Treatment for NSCLC

07/07/2016

JCP Editors

Nivolumab has demonstrated encouraging activity and acceptable tolerability as a first-line treatment for patients with advanced non-small cell lung cancer (NSCLC), according to the results of two phase I,...

...

07/07/2016

Journal of Clinical Pathways

Research in Review

Blood Biomarkers Useful for Understanding NSCLC Prognosis

06/20/2016

JCP Editors

A study of patients with inoperable non-small cell lung cancer (NSCLC) has found that certain blood biomarkers may have prognostic value and could enhance treatment decision-making for providers.  To...

...

06/20/2016

Journal of Clinical Pathways